We have developed a highly sensitive, two-site immunoradiometric assay (IRMA) for human parathyrin (PTH) that is specific for the intact, secreted, biologically active 84-aminoacid peptide. This assay has several technical advantages: it does not detect even high concentrations of inactive carboxyl-terminal fragments, results are available within 24 h, and the detection limit for intact hormone is low (1 ng/L). The assay readily measures concentrations of PTH in all healthy subjects and distinguishes these values from low or undetectable PTH values observed in clinical situations in which PTH secretion is expected to be suppressed. We found complete separation of results from 37 patients with surgically proven hyperparathyroidism and those from 23 patients with hypercalcemia associated with malignancy, the latter having PTH values at or below the lower limits of normal for this assay. The sensitivity, specificity, and rapid turnaround time of this two-site IRMA should advance the laboratory evaluation of patients with disorders of calcium metabolism.
developing monoclonal antibodies of requisite sensitivity for PTH (6) . We have circumvented these practical limitations by harvesting large volumes of antisera from goats and by preparing immunological reagents having specificity restricted to the desired epitopes on the PTH molecule, using affinity purification with selected hormone-fragment ligands immobilized to a solid phase. The quantities of antisera harvested are sufficient to assure the stability of this assay for at least several decades.
Here we describe the development of a two-site immunoradiometric assay (ntr&) for PTH, based on affinity-purified polyclonal antisera: one group of which are specific for the amino-terminal 1-34 portion of the PTH molecule, the other for the 39-84 amino acid sequence. With this assay, one detects only biologically active intact PTH, with no interference from circulating PTH fragments. The assay provides all of the advantages of mMA methodology and, most importantly, it has completely differentiated patients with surgically proven hyperparathyroidism from patients with hypercalcemia of malignancy.
MaterIals and Methods

Reagents
We raised antisera in goats immunized with partly purified human PTH from human parathyroid adenomatous glands. After preparing two separate immunoaffinity The antiserum that had been immunoaffinity-purified to bind human PTH(39-84) was diluted in pH 7.4 phosphate buffer to 1.5 g/mL, then immobilized by adsorption onto 8-mm-diameter polystyrene beads (Precision Plastic Ball Co., Chicago, IL). The immunofflnity-purified antibody to human PTH(1-34) was radioiodinated with im1 by the Chloramine T procedure (7) to a specific activity of 30 CiJg, and diluted in phosphate-buffered saline (0.6 mollL phosphate buffer containing 9.0 g of sodium chloride, 1.0 g of bovine serum albumin, and 1.0 g of sodium azide per liter, pH 7. 1 mL of Triton X-100 per liter, and count the radioactivity of each bead for 1 mm in a gamma spectrometer.
Subjects
On the day before surgical neck exploration, we obtained serum samples from 37 consecutive patients with hypercalcemia who, by clinical and laboratory evaluation, were thought to have hyperparathyroidism that required surgical cure. All of these patients, who were surgically explored for hyperparathyroidism by our Endocrine Surgical Service, are included in our series. All had operative findings, confirmed histologically, of parathyroid adenoma or four-gland parathyroid hyperplasia, and all had normalization of their calcium concentrations in serum after successful neck surgery. We also measured Fl'H in serum from 23 patients with hypercalcemia and various cancers, evident clinically and proven pathologically, from either our inpatient Oncology Service or from the office practices of physicians at this hospital. Approximately half of these patients had metastases to the skeleton associated with breast and lung cancer; the others had hypophosphatemia with no evidence of skeletal metastases, and represent humoral hypercalcemia of malignancy (8, 9) . To establish the normal reference interval, we used serum samples obtained from 72 healthy blood donors in Boston, none of whom were clinically suspected of having disorders of calcium metabolism.
Results
Assay Characteristics
For convenience we plotted the assay dose-response, the corrected counts/mm (counts/mm for each standard minus the counts/mm for the zero standard) vs concentrations of PTH 1-84, on log-log paper for standard concentrations between 15 and 1500 ng/L; for lower concentrations (between zero and 45 ng/L) a linear plot is more convenient (Figure 1 ) and permits accurate determination of FF11 values over that range. Values of unknowns were read directly from the plots. In practice, the detection limit of the assay is 1 ng/L, based on precision in counting small amounts of bound radioactivity. To determine whether fragments of VFH react or otherwise interfere with measurement of intact human FFH by our two-site IRMA, we used it to assay the synthetic peptides assay from 20 replicate determinations of two qualitycontrol sera in a single assay. The reproducibility (interassay variance) was calculated from data obtained over four weeks, during which we made an additional 20 determinations of these two control sera. The intra-assay CV ranged from 1.8% to 3.4%, the inter-assay CV from 5.6% to 6.1%. We further assessed the utility of the assay by studying analytical recovery and parallelism. Various amounts of exogenous PTH 1-84 were added to a series of patients' samples, then measured by the IRMA; analytical recovery ranged from 93% to 105% (Table 1) . Parallelism was assessed by use of a series of dilutions in zero standard for three patients' samples. These results show excellent agreement with predicted values (Table 2) .
Clinical Studies
We determined the normal reference values for this assay as 12-65 ngIL, using nonparametric analysis of the 72 blood donors' sera by calculating +2 SD from their geometric mean of 28 ng/L.
Assay results for 37 individuals with surgically proven hyperparathyroidism were completely resolved from those for 24 patients with hypercalcemia of malignancy ( Figure  2 ). All patients with surgically proven hyperparathyroidism had increased FF11 concentrations except for two persons whose FF11 was at the upper limit of normal. Ten patients with malignancy had undetectable concentrations of parathyroid hormone, and 13 were below the lower limit of normal. FF11 values in hyperparathyroidism and hypercalcomia of malignancy were extremely widely separated at high concentrations of serum calcium; even for borderline increases of serum calcium there was no overlap (Figure 3) .
DIscussion
Biologically active intact FF11 is secreted as an 84-aminoacid peptide; peripheral metabolism and intraglandular proteolytic modification of the hormone result in circulating peptide fragments that are principally middle and carboxylterminal biologically inactive fragments (1, 1O-12) . Biologically active intact PTH 1-84 has a half-life of <5 mm, whereas the inactive middle and carboxyl-termmnal frag- Therefore, the ideal FFH assay for clinical situations involving assessment of calcium metabolism is one that is highly sensitive, specific for intact hormone, and free of nonspecific serum effects. These goals are satisfied by the mr for FFH that we describe. Sensitivity for intact hormone is high, and low values can be distinguished from those in normal subjects. The intrinsic affinity of the antisera for PTH is high, but less than needed for conventional radioimmunoassays, which suggests cooperative interaction among multiple antibodies (15). Specificity for intact hormone is accomplished by selecting antisera that recognize epitopes in widely divergent regions of the FFH peptide. Although both intact hormone and middle-carboxyl terminal fragments are bound to the "capture" antisera, the 125j.. labeled amino-terminal antisera will bind only intact hormone and not middle-carboxyl terminal fragments; increasing counts bound correlate directly with the amount of intact hormone captured by the first antisera. The wide range of concentration over which the assay can be used without loss of precision (approximately 500-fold), and the one-day turnaround time are important technical advantages that also make patient care more timely by expediting correct diagnosis and institution of appropriate therapy. It is vital for the clinician to establish the cause for hypercalcemia. diagnosis (3, 18, 19) .
The explanation for the observations of apparent immunoreactive PTH in the blood of patients with hypercalcemia associated with malignancy is still unresolved. Chromatographic and mRNA analyses of tumor extracts have provided no evidence that tumors associated with hypercalcemia produce FF11 (20) , and the biological activity of factors that appear to bind to the PTH receptor is not blocked by antisera to PT!! (21) . Most likely, the apparent increase of FF11 seen in conventional competitive radioimmunoassays are nonspecific effects from factors in plasma from cancer patients, which interfere with binding of radiolabeled PTH to its antibody; alternatively, there could be sequence homology between PTH and factors responsible for hormonal hypercalcemia of malignancy. The unique approach in our two-site immunoradiometric assay-the use of two distinct antisera pools, each recognizing a sequence within FF11-seems to eliminate the false "signals" from nonspecific effects that appear in competitive radioimmunoassays.
We are continuing an extensive evaluation of this assay in a wide spectrum of clinical conditions, such as hypoparathyroidism, pseudohypoparathyroidism, renal failure, and other forms of secondary hyperparathyroidism; dynamic testing with alterations in calcium is also being explored. 
